# Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Source: https://onco.cc/trials/nct07334119/  
OnCo record `nct07334119` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MT-304 run by Myeloid Therapeutics, now recruiting.

## Summary

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors is a phase 1 interventional study registered as NCT07334119 by Myeloid Therapeutics, with 60 participants planned, started 2025-11-25, primary completion expected 2027-01-31. Conditions recorded: HER2-Expressing Solid Tumors. Interventions recorded: MT-304, MT-304 + Nivolumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07334119
- Phase: 1
- Setting: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
- Sponsor: Myeloid Therapeutics
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07334119: https://clinicaltrials.gov/study/NCT07334119

## Connected records

- drugs: [MT-304](https://onco.cc/drugs/mt-304/)
- companies: [CREATE Medicines](https://onco.cc/companies/create-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07334119.json